Share price very undervalued still !!!

I decided to start another thread on Neu following up the original post I put on hot copper headed share price on 19 th of October 2021 with the following comparisons .
1. Capitalization then $233 mill now $.1.35 billion .
2. $35 mill in the bank then compared to $230 mill now .
3. DAYBUE drug approved by FDA now .
4.First Royalty cheque for DAYBUE due now of approx $4 mill for last shortened quarter ,next quarter should be approx $8 mill with power to grow .
5. Many milestones to come subject to sales .
6. Priority Review Voucher earnt which is worth approx $50 mill to come .
7. Earning approx $12 mill a year in interest received .
8. 4 Phase 2 trials been done on NNZ2591 with first results just the end of this calendar year .
9. Row sold for approx $150 mill and I heard at a recent broker update that the purchaser was not known until the very last minute and that the competition was from very large pharma companies
10.In my opinion Neu is no longer solely a biotech but a pharma /biotech company .
11. If large pharmas were interested in ROW then I would not be surprised if they are still sniffing around NEU .
12. I believe the directors and management have done a great job up to date but it is now time to appoint a share marketing company to help with lining up brokers and fund managers and really market the company before we get real takeover interest.